Clinical Trial Update: A Follow-up Assessment of Resistance to ABT-333 in Hepatitis C Virus (HCV)-Infected Subjects Who Have Received ABT-333 in ABT-333 Studies [Phase 2]

View source ↗

Summary

Phase 2 follow-up study evaluating resistance to ABT-333 in hepatitis C patients who previously received ABT-333; results posted 2015-01-08.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• ABT-333 (ABT-333)

Snippet

Sponsor: AbbVie (prior sponsor, Abbott) | Conditions: HCV Infection | Phase 2 | Status: COMPLETED | Results posted: 2015-01-08